PVI
RLMD icon

Pura Vida Investments’s Relmada Therapeutics RLMD Stock Holding History

Pura Vida Investments’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-20,000
Closed -$69.8K – 152
2022
Q4 		$69.8K Buy
+20,000
New +$176K ﹤0.01% 187

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pura Vida Investments's RLMD Position: Q1 2023 in Review

Pura Vida Investments sold out of Relmada Therapeutics (RLMD) in Q1 2023, closing a stake of 22,233 shares — an estimated $77.6K sold.

Pura Vida Investments first reported a position in RLMD in Q4 2021 and held it in 3 quarters. The position peaked at $402K in Q1 2022. 91 funds tracked by Wall St. Rank hold RLMD as of Q1 2023.

  • Pura Vida Investments reported no remaining Relmada Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Pura Vida Investments sold 22,233 Relmada Therapeutics shares in Q1 2023, an estimated $77.6K.
  • Pura Vida Investments first reported a position in Relmada Therapeutics in Q4 2021 and held it in 3 quarters.
  • Pura Vida Investments's Relmada Therapeutics position peaked at $402K in Q1 2022.
  • 91 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q1 2023.

Based on Pura Vida Investments's 13F filing for Q1 2023, filed 15 May 2023.